Cingulate shares are trading higher after the company announced it received guidance from the FDA regarding its clinical program for CTx-1301. Based on the guidance, the company expects to submit the NDA for CTx-1301 in the first half of 2025.

CINGULATE INC. -15.33% Pre

CINGULATE INC.

CING

0.78

0.78

-15.33%

0.00% Pre

Cingulate shares are trading higher after the company announced it received guidance from the FDA regarding its clinical program for CTx-1301. Based on the guidance, the company expects to submit the NDA for CTx-1301 in the first half of 2025.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via